FZ 010 - Fzata

Alternative Names: FZ-010 - Fzata

Latest Information Update: 18 Sep 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fzata
Class Antihyperglycaemics; Gene therapies; Obesity therapies; Probiotics; Yeasts
Mechanism of Action Gastrointestinal microbiome modulators; Interleukin-22 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

29 Aug 2024 Fzata has patent protection for BioPYM technology platform in USA (Fzata pipeline, August 2024)
09 Aug 2024 Fzata pipeline, August 2024: New profile created based on the company pipeline. As genetic modification is involved, DC is considered as gene therapies. MOA added as per understanding from the pipeline
09 Aug 2024 Preclinical trials in Diabetes mellitus in USA (PO) before August 2024 (Fzata pipeline, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com